Increased toxicities associated with dose escalation of stereotactic body radiation therapy in prostate cancer: results from a phase I/II study.
Takero HirataOsamu SuzukiKeisuke OtaniAkimitsu MiyakeKeisuke TamariYuji SeoFumiaki IsohashiNaoki KaiKoji HatanoKazutoshi FujitaMotohide UemuraRyoichi ImamuraSetsuo TamenagaYutaro YoshinoYasutoshi FumimotoYasuo YoshiokaNorio NonomuraKazuhiko OgawaPublished in: Acta oncologica (Stockholm, Sweden) (2023)
An SBRT dose of 35 Gy per 5 fractions is less likely to cause adverse events in patients with PCa than 375- and 40-Gy SBRT doses. Higher doses of SBRT should be applied with caution.